Clinuvel Pharmaceuticals Ltd ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $10.34
- Today's High:
- $10.8
- Open Price:
- $10.34
- 52W Low:
- $9.1521
- 52W High:
- $19.98
- Prev. Close:
- $10.96
- Volume:
- 17300
Company Statistics
- Market Cap.:
- $634.90 million
- Book Value:
- 2.817
- Revenue TTM:
- $70.89 million
- Operating Margin TTM:
- 57.17%
- Gross Profit TTM:
- $56.92 million
- Profit Margin:
- 37.24%
- Return on Assets TTM:
- 18.36%
- Return on Equity TTM:
- 21.42%
Company Profile
Clinuvel Pharmaceuticals Ltd ADR had its IPO on under the ticker symbol CLVLY.
The company operates in the Healthcare sector and Biotechnology industry. Clinuvel Pharmaceuticals Ltd ADR has a staff strength of 0 employees.
Stock update
Shares of Clinuvel Pharmaceuticals Ltd ADR opened at $10.34 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $10.34 - $10.8, and closed at $10.62.
This is a -3.1% slip from the previous day's closing price.
A total volume of 17,300 shares were traded at the close of the day’s session.
In the last one week, shares of Clinuvel Pharmaceuticals Ltd ADR have slipped by -13.34%.
Clinuvel Pharmaceuticals Ltd ADR's Key Ratios
Clinuvel Pharmaceuticals Ltd ADR has a market cap of $634.90 million, indicating a price to book ratio of 8.4651 and a price to sales ratio of 10.6338.
In the last 12-months Clinuvel Pharmaceuticals Ltd ADR’s revenue was $70.89 million with a gross profit of $56.92 million and an EBITDA of $40.94 million. The EBITDA ratio measures Clinuvel Pharmaceuticals Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Clinuvel Pharmaceuticals Ltd ADR’s operating margin was 57.17% while its return on assets stood at 18.36% with a return of equity of 21.42%.
In Q2, Clinuvel Pharmaceuticals Ltd ADR’s quarterly earnings growth was a positive 93% while revenue growth was a positive 19.2%.
Clinuvel Pharmaceuticals Ltd ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 48.7308
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0.26 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Clinuvel Pharmaceuticals Ltd ADR’s profitability.
Clinuvel Pharmaceuticals Ltd ADR stock is trading at a EV to sales ratio of 9.6704 and a EV to EBITDA ratio of 17.015. Its price to sales ratio in the trailing 12-months stood at 10.6338.
Clinuvel Pharmaceuticals Ltd ADR stock pays annual dividends of $0.04 per share, indicating a yield of 0.22% and a payout ratio of 6.2%.
Balance sheet and cash flow metrics
- Total Assets
- $143.95 million
- Total Liabilities
- $13.73 million
- Operating Cash Flow
- $-188997.00
- Capital Expenditure
- $188997
- Dividend Payout Ratio
- 6.2%
Clinuvel Pharmaceuticals Ltd ADR ended 2024 with $143.95 million in total assets and $0 in total liabilities. Its intangible assets were valued at $143.95 million while shareholder equity stood at $125.56 million.
Clinuvel Pharmaceuticals Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $13.73 million in other current liabilities, 151849375.00 in common stock, $-38402428.00 in retained earnings and $185030.00 in goodwill. Its cash balance stood at $121.51 million and cash and short-term investments were $121.51 million. The company’s total short-term debt was $315,068 while long-term debt stood at $0.
Clinuvel Pharmaceuticals Ltd ADR’s total current assets stands at $140.58 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $16.20 million compared to accounts payable of $259199.00 and inventory worth $1.83 million.
In 2024, Clinuvel Pharmaceuticals Ltd ADR's operating cash flow was $-188997.00 while its capital expenditure stood at $188997.
Comparatively, Clinuvel Pharmaceuticals Ltd ADR paid $0.06 in dividends in 2024.
Other key metrics
- Current Trading Price
- $10.62
- 52-Week High
- $19.98
- 52-Week Low
- $9.1521
- Analyst Target Price
- $
Clinuvel Pharmaceuticals Ltd ADR stock is currently trading at $10.62 per share. It touched a 52-week high of $19.98 and a 52-week low of $19.98. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $12.17 and 200-day moving average was $13.42 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 1.9% are held by institutions.
Frequently Asked Questions About Clinuvel Pharmaceuticals Ltd ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company’s pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People’s Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.